MiR-21 and Tocilizumab interactions improve COVID-19 myocarditis outcomes.

ABSTRACT:

Background

Myocarditis is now one of the most fatal and morbid complications of COVID-19. Many scientists have recently concentrated on this problem.

Objectives

This study assessed the effects of Remdesivir (RMS) and Tocilizumab (TCZ) in COVID-19 myocarditis.

Design

Observational, cohort study.

Methods

Patients with COVID-19 myocarditis were enrolled in the study and divided into three groups, TCZ-treated, RMS-treated, and Dexamethasone-treated patients. After 7 days of treatment, patients were reassessed for improvement.

Results

TCZ significantly improved patients' ejection fraction in 7 days, but it had limited efficacy. RMS improved inflammatory characteristics of the disease, but RMS-treated patients showed exacerbated cardiac function over 7 days, a

SUBMITTER: Hossein Heydari A 

PROVIDER: S-EPMC10333985 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature